Jefferies Financial Group lowered shares of Synthorx (NASDAQ:THOR) from a buy rating to a hold rating in a research note published on Thursday, BenzingaRatingsTable reports. The firm currently has $68.00 price target on the medical instruments supplier’s stock, up from their previous price target of $23.00.
Other equities analysts have also recently issued reports about the company. Svb Leerink reaffirmed a market perform rating and issued a $68.00 target price on shares of Synthorx in a report on Wednesday, December 11th. Evercore ISI reissued a buy rating and set a $35.00 price target on shares of Synthorx in a report on Sunday, November 24th. Zacks Investment Research raised Synthorx from a hold rating to a buy rating and set a $22.00 price target on the stock in a report on Saturday, November 9th. ValuEngine upgraded Synthorx from a hold rating to a buy rating in a research report on Thursday, December 5th. Finally, Leerink Swann lowered Synthorx from an outperform rating to a market perform rating and set a $68.00 price objective for the company. in a research note on Wednesday, December 11th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Synthorx has a consensus rating of Hold and an average price target of $48.50.
Shares of NASDAQ:THOR opened at $68.02 on Thursday. The stock’s 50-day simple moving average is $29.49 and its two-hundred day simple moving average is $18.82. Synthorx has a 52-week low of $11.05 and a 52-week high of $68.05.
Synthorx (NASDAQ:THOR) last released its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.12. As a group, equities analysts anticipate that Synthorx will post -1.54 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of THOR. Wells Fargo & Company MN increased its holdings in Synthorx by 156.5% in the 2nd quarter. Wells Fargo & Company MN now owns 12,056 shares of the medical instruments supplier’s stock valued at $162,000 after acquiring an additional 7,356 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Synthorx by 1.4% in the second quarter. Charles Schwab Investment Management Inc. now owns 61,599 shares of the medical instruments supplier’s stock worth $833,000 after purchasing an additional 874 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Synthorx by 24.4% in the second quarter. Bank of New York Mellon Corp now owns 22,002 shares of the medical instruments supplier’s stock worth $297,000 after purchasing an additional 4,311 shares during the last quarter. Matisse Capital lifted its position in shares of Synthorx by 8.9% in the second quarter. Matisse Capital now owns 70,033 shares of the medical instruments supplier’s stock worth $946,000 after buying an additional 5,700 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Synthorx by 1.6% in the second quarter. Northern Trust Corp now owns 92,542 shares of the medical instruments supplier’s stock worth $1,251,000 after buying an additional 1,483 shares in the last quarter. 66.11% of the stock is owned by institutional investors.
About Synthorx
Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company’s lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.